Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. ⁶⁸Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, ¹⁸F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [¹⁸F]FAPI-74 prospectively in a small patient cohort.

Methods

Eight patients underwent both [¹⁸F]FAPI-74-PET/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters.

Results

We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung.

Conclusion

The initial results confirm our assumption that [¹⁸F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.

中文翻译：

---

[18F]FAPI-74 PET/CT 在特发性肺纤维化中的初步结果

摘要

特发性肺纤维化（IPF）是一种预后不良的慢性纤维化间质性肺疾病。 ⁶⁸Ga标记的FAP配体由于活化的成纤维细胞在肺纤维化成像中的关键作用而表现出非常有希望的结果。然而，¹⁸F 标记的 FAP 配体可能会提供质量更高的成像结果，并因大规模生产而带来经济效益。因此，我们试图在小型患者队列中前瞻性研究 [¹⁸F]FAPI-74 的潜力。

方法

8 名患者接受了 [¹⁸F]FAPI-74-PET/CT 和 HRCT 扫描，然后与未接受扫描的对照组进行比较任何纤维化肺部疾病。概要分析了纤维化肺区域示踪剂的摄取情况以及放射学和临床参数。

结果

我们观察到纤维化活动量、Hounsfield 量表以及肺活量和弥散能力之间呈正相关。

结论

初步结果证实了我们的假设：[¹⁸F]FAPI-74 为肺纤维化变化提供了一种可行的非侵入性评估方法。 IPF患者。